Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National Survey
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, debilitating conditions that can have important economic and clinical implications.
To quantify individual and national estimates of the health care and patient out-of-pocket (OOP) costs of CD and UC.
In a retrospective study using 1996 to 2009 data from the Medical Expenditure Panel Survey, individuals’ self-reported health conditions were mapped to International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic codes. Individuals with a code of 555.x (CD) or 556.x (UC) were identified. Health care services and costs included prescriptions and inpatient, outpatient, emergency room, office, and home health services. OOP costs were the portion of individuals’ total payments for health care services.
There were 358 individuals with CD (mean age 49.0 years; 55 % female), 198 individuals with UC (mean age 47.1 years; 64 % female), and 206,993 individuals without inflammatory bowel disease (IBD) (mean age 48.2 years; 58 % female). Annual per capita health insurer and OOP costs for individuals with CD were greater than those without IBD ($9,526 versus $3,781, p < 0.001 and $1,603 versus $866, p < 0.001, respectively). Health insurer and OOP costs were greater for UC compared with those without IBD ($6,443 versus $3,781, p < 0.001 and $1,263 versus $866, p < 0.001, respectively). US national aggregate annual estimates of health insurer, OOP, and total direct costs secondary to CD are $2.04 billion, $0.26 billion, and $2.29 billion, respectively. Aggregate health insurer, OOP, and total direct costs attributable to UC are $0.53 billion, $0.07 billion, and $0.61 billion, respectively.
The direct costs associated with CD and UC are substantial. The extent to which appropriate diagnosis and treatment reduces the total health care costs for individuals with CD or UC should be examined.
- Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429. CrossRef
- Loftus EV Jr, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther. 2002;16:51–60. CrossRef
- Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology. 1991;100:143–149.
- Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut. 1996;39:690–697. CrossRef
- Calkins BM, Lilienfeld AM, Garland CF, Mendeloff AI. Trends in incidence rates of ulcerative colitis and Crohn’s disease. Dig Dis Sci. 1984;29:913–920. CrossRef
- Stowe SP, Redmond SR, Stormont JM, et al. An epidemiologic study of inflammatory bowel disease in Rochester, New York. Hospital incidence. Gastroenterology. 1990;98:104–110.
- Roth MP, Petersen GM, McElree C, Feldman E, Rotter JI. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology. 1989;97:900–904.
- Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–1385. CrossRef
- Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol. 2009;104:465–483.
- Cohen JL, Strong SA, Hyman NH, et al. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2005;48:1997–2009. CrossRef
- Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore). 1976;55:401–412. CrossRef
- Barreiro-de Acosta M, Domínguez-Muñoz JE, Núñez-Pardo de Vera MC, Lozano-León A, Lorenzo A, Peña S. Relationship between clinical features of Crohn’s disease and the risk of developing extraintestinal manifestations. Eur J Gastroenterol Hepatol. 2007;19:73–78. CrossRef
- Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009;33:854–862. CrossRef
- Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430–434.
- Solem CA, Loftus EV, Tremaine WJ, Sandborn WJ. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99:97–101. CrossRef
- Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut. 1994;35:950–954. CrossRef
- Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000;95:677–683. CrossRef
- Hillson E, Dybicz S, Waters HC, et al. Health care expenditures in ulcerative colitis: the perspective of a self-insured employer. J Occup Environ Med. 2008;50:969–977. CrossRef
- Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135:1907–1913. CrossRef
- Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50:1261–1272. CrossRef
- Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn’s disease. Am J Gastroenterol. 2000;95:524–530. CrossRef
- Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. Survey Background. Agency for Healthcare Research and Quality Web site. Available at: http://www.meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp. Accessed March 12, 2009.
- Cohen JW, Monheit AC, Beauregard KM, et al. The Medical Expenditure Panel Survey: a national health information resource. Inquiry. 1996–1997;33:373–389.
- Cohen SB, DiGaetano R, Goksel H. Methodology Report #5: Estimation Procedures in the 1996 MEPS Household Component. Agency for Healthcare Research and Quality Web site. Available at: http://meps.ahrq.gov/mepsweb/data_files/publications/mr5/mr5.shtml. Published May 1999. Accessed March 12, 2010.
- Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. MEPS-HC Response Rates by Panel. Agency for Healthcare Research and Quality Web site. Available at: http://meps.ahrq.gov/mepsweb/survey_comp/hc_response_rate.jsp. Accessed February 10, 2010.
- Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. MEPS Expenditures. MEPS-HC Summary Data Tables Technical Notes. Agency for Healthcare Research and Quality Web site. Available at: http://meps.ahrq.gov/mepsweb/survey_comp/hc_technical_notes.shtml#expenditures. Published May 2004. Accessed April 18, 2012.
- Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Health. 2001;4:329–334.
- Cragg JG. Some statistical models for limited dependent variables with application to the demand for durable goods. Econometrica. 1971;39:829–844. CrossRef
- Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ. 2004;23:525–542. CrossRef
- Mullahy J. Much ado about two: reconsidering retransformation and the two-part model in health econometrics. J Health Econ. 1998;17:247–281. CrossRef
- Kotlarz H, Gunnarsson CL, Fang H, Rizzo JA. Insurer and out-of-pocket costs of osteoarthritis in the US: evidence from national survey data. Arthritis Rheum. 2009;60:3546–3553. CrossRef
- United States Census Bureau. Table HI01. Health Insurance Coverage Status and Type of Coverage by Selected Characteristics: 2010 All Races. United States Census Bureau Web site. Available at: http://www.census.gov/hhes/www/cpstables/032011/health/h01_001.htm. Accessed March 2, 2010.
- Shanahan F, Bernstein CN. The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol. 2009;25:301–305. CrossRef
- US Department of Health and Human Services, Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2007. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf. Accessed January 31, 2010.
- National Heart, Lung and Blood Institute. Incidence and Prevalence: 2006 Chart Book on Cardiovascular and Lung Diseases. National Heart, Lung, and Blood Institute Web site. Available at: http://www.nhlbi.nih.gov/resources/docs/06a_ip_chtbk.pdf. Published May 2006. Accessed April 6, 2008.
- US Bureau of Labor Statistics. National Compensation Survey: Occupational Wages in the United States, July 2003. (Bulletin 2568). US Bureau of Labor Statistics Web site. Available at: http://stats.bls.gov/ncs/ocs/sp/ncbl0658.pdf. Published September 2004. Accessed February 10, 2010.
- Blumenthal D. Employer-sponsored insurance—riding the health care tiger. N Engl J Med. 2006;355:195–202. CrossRef
- Blumenthal D. Employer-sponsored health insurance in the United States—origins and implications. N Engl J Med. 2006;355:82–88. CrossRef
- Collins SR, Davis K, Ho A. A shared responsibility: US employers and the provision of health insurance to employees. Inquiry. 2005;42:6–15. CrossRef
- Machlin S, Cohen J, Elixhauser A, Beauregard K, Steiner C. Sensitivity of household reported medical conditions in the Medical Expenditure Panel Survey. Med Care. 2009;47:618–625. CrossRef
- Direct Health Care Insurer and Out-of-Pocket Expenditures of Inflammatory Bowel Disease: Evidence from a US National Survey
Digestive Diseases and Sciences
Volume 57, Issue 12 , pp 3080-3091
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Costs and cost analysis
- Crohn’s disease
- Health care costs
- Health expenditures
- Inflammatory bowel disease
- Ulcerative colitis
- Industry Sectors
- Author Affiliations
- 1. S2 Statistical Solutions, Inc., 11176 Main Street, Cincinnati, OH, 45241, USA
- 2. Department of Political Science, Economics, and Philosophy, College of Staten Island, CUNY, 2N-229, 2800 Victory Boulevard, Staten Island, NY, 10314, USA
- 8. Department of Health Services Administration, School of Public Health, University of Maryland, 3310A School of Public Health Building, College Park, MD, 20742, USA
- 3. Department of Preventive Medicine, Stony Brook University, Stony Brook, NY, 11794, USA
- 4. Department of Economics, Stony Brook University, Stony Brook, NY, 11794, USA
- 5. Harvard Medical School, 25 Shattuck Street, Boston, MA, 02115, USA
- 6. Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02115, USA
- 9. Department of Population Medicine, New York University, 550 1st Avenue, VZ30 6th Floor, New York, NY, 10012, USA
- 7. Janssen Scientific Affairs, LLC, 850 Ridgeview Drive, Horsham, PA, 19044, USA